6results about How to "Clear treatment effect" patented technology

The invention relates to application of tsRNA-3025a as a prognostic marker of acute myocardial infarction and a treatment target spot of myocardial ischemia reperfusion injury. A DNA (Deoxyribonucleic Acid) sequence corresponding to the tsRNA-3025a is shown as SEQ ID NO: 1: 5 '-ATCCTGCCGACTACGCCA-3'. The tsRNA-3025a can be used for treating acute myocardial infarction and myocardial ischemia reperfusion injury. In the aspect of prognosis, a detection kit is provided, and the risk of heart failure and short-term adverse events of a patient is evaluated by quantitatively detecting the expression level of the tsRNA. In the aspect of treatment, the invention provides the application of the anti-tagomir for inhibiting the function or expression of tsRNA-3025a in the preparation of the medicine for treating the myocardial ischemia reperfusion injury, and the anti-tagomir is subjected to specific chemical modification. A novel biomarker is provided for prognosis risk stratification of acute myocardial infarction, and an effective treatment strategy is provided for prevention and treatment of myocardial ischemia-reperfusion injury.

This invention belongs to the field of medical technology, specifically relating to the application of mitochondrial transplantation to regulate the immune-metabolic network in the treatment of myocardial dysfunction after cardiac arrest. The mitochondrial transplantation is performed within 0.5-2 hours after the restoration of spontaneous cardiac circulation. This technical solution, through multi-omics integrated analysis, proposes that mitochondrial transplantation exerts a cardioprotective effect by regulating the immune-metabolic-mitochondrial triaxial synergistic network, providing a new research direction for the precision treatment of myocardial dysfunction after cardiac arrest.

This application discloses the use of itaconic acid derivatives in the preparation of drugs for treating candidemia, belonging to the field of biomedical technology. The itaconic acid derivatives proposed in this application are dimethyl itaconic acid and / or 4-octyl itaconic acid. Dimethyl itaconic acid exhibits a dose-dependent therapeutic effect in model mice, with an optimal dose of 1200 mg / kg improving survival rate and reducing kidney damage; 4-octyl itaconic acid can enhance the anti-Candida albicans ability of macrophages and regulate the expression of inflammatory factors. The application of the itaconic acid derivatives proposed in this application in the treatment of candidemia works through immunomodulation, circumventing fungal resistance. Furthermore, the drugs are low in toxicity, have good biocompatibility, and use a universal experimental system, providing a new approach for the clinical treatment of candidemia with broad application prospects. This application also protects pharmaceutical compositions for treating candidemia with dimethyl itaconic acid and / or 4-octyl itaconic acid as active ingredients.

The invention provides a small molecule compound A5 with a good treatment effect on metabolism-related fatty liver diseases, a novel pyrene derivative A5 is successfully prepared through an organic synthesis approach, and the novel pyrene derivative A5 is proved to have a definite treatment effect on the metabolism-related fatty liver diseases on the basis of in-vivo and in-vitro pharmacodynamic experiments. The invention further provides an application of the hydroxypyrene derivative A5 in preparation of drugs for preventing and / or treating metabolism-related fatty liver diseases. The compound can remarkably improve characteristic pathological changes of the metabolism-related fatty liver disease, including regulation of dyslipidemia, inhibition of hepatocyte vacuolar degeneration and delay of liver fibrosis progress, shows the advantage of multi-target treatment, and shows a remarkable curative effect in treatment of the metabolism-related fatty liver disease.

The application discloses a traditional Chinese medicine composition for preventing and treating Hashimoto's thyroiditis and complications (thyroid nodules and / or mammary gland hyperplasia), which is prepared from raw medicinal materials in the following proportions: 1-10 parts of ginseng, 1-15 parts of astragalus, 1-40 parts of fritillaria, 1-20 parts of prunella vulgaris, 1-20 parts of smilax, 1-18 parts of curcuma, and 1-19 parts of scutellaria. In addition, the application also discloses a preparation method and application of the traditional Chinese medicine composition. Clinical efficacy and pharmacological researches prove that the traditional Chinese medicine composition has multiple effects of clearing heat and resolving toxins, promoting blood circulation to remove blood stasis, and tonifying qi and invigorating the spleen, so that the purposes of dispersing thyroid nodules, reducing mammary gland hyperplasia, and improving Hashimoto's thyroiditis symptoms are achieved.

The present application relates to the technical field of traditional Chinese medicine preparation, and discloses a traditional Chinese medicine composition with cough-relieving effect and a preparation method thereof, which is composed of one or both of crude drug powder of summerleaf euonymus and summerleaf euonymus extract, and contains the following components in mass fraction: 1-15 parts of summerleaf euonymus crude drug powder and 1-10 parts of summerleaf euonymus extract.In the present application, the medicinal activity of summerleaf euonymus in the field of cough relief is found and verified, the therapeutic effect of summerleaf euonymus on various types of cough is determined, the application limitation of summerleaf euonymus in the prior art, i.e. only used for promoting blood circulation to remove meridian obstruction and relieving qi stagnation and pain, is broken, and the clinical application range and medicinal value of summerleaf euonymus are greatly expanded.